prikaz prve stranice dokumenta Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
  Download
PDF 1.14 MB
Scientific paper - Review paper
Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
Journal of Clinical Medicine, 12 (2023), 3; 1139. https://doi.org/10.3390/jcm12031139
Tešanović Perković, Deša; Bukvić Mokos, Zrinka; Marinović, Branka

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Tešanović Perković, D., Bukvić Mokos, Z. & Marinović, B. (2023). Epidermolysis Bullosa Acquisita—Current and Emerging Treatments. Journal of Clinical Medicine, 12. (3). doi: 10.3390/jcm12031139

Tešanović Perković, Deša, et al. "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments." Journal of Clinical Medicine, vol. 12, no. 3, 2023. https://doi.org/10.3390/jcm12031139

Tešanović Perković, Deša, Zrinka Bukvić Mokos and Branka Marinović. "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments." Journal of Clinical Medicine 12, no. 3 (2023). https://doi.org/10.3390/jcm12031139

Tešanović Perković, D., Bukvić Mokos, Z. and Marinović, B. (2023) 'Epidermolysis Bullosa Acquisita—Current and Emerging Treatments', Journal of Clinical Medicine, 12(3). doi: 10.3390/jcm12031139

Tešanović Perković D, Bukvić Mokos Z, Marinović B. Epidermolysis Bullosa Acquisita—Current and Emerging Treatments. Journal of Clinical Medicine [Internet]. 2023 February 01 [cited 2024 May 28];12(3). doi: 10.3390/jcm12031139

D. Tešanović Perković, Z. Bukvić Mokos and B. Marinović, "Epidermolysis Bullosa Acquisita—Current and Emerging Treatments", Journal of Clinical Medicine, vol. 12, no. 3, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:702457. [Accessed: 28 May 2024]

Metadata
Title (english)Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
AuthorDeša Tešanović Perković
AuthorZrinka Bukvić Mokos
AuthorBranka Marinović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Dermatology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Abstract (english)
Epidermolysis bullosa acquisita (EBA) is a rare chronic autoimmune subepidermal blistering disease of the skin and mucous membranes, usually beginning in adulthood. EBA is induced by autoantibodies to type VII collagen, a major component of anchoring fibrils in the dermal–epidermal junction (DEJ). The binding of autoantibodies to type-VII collagen subsequently leads to the detachment of the epidermis and the formation of mucocutaneous blisters. EBA has two major clinical subtypes: the mechanobullous and inflammatory variants. The classic mechanobullous variant presentation consists of skin fragility, bullae with minimal clinical or histological inflammation, erosions in acral distribution that heal with scarring, and milia formation. The inflammatory variant is challenging to differentiate from other autoimmune bullous diseases, most commonly bullous pemphigoid (BP) but also mucous membrane pemphigoid (MMP), Brunsting–Perry pemphigoid, and linear IgA dermatosis. Due to its recalcitrance conventional treatment of epidermolysis bullosa acquisita is shown to be demanding. Here we discuss novel therapeutic strategies that have emerged and which could potentially improve the quality of life in patients with EBA.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 12, no. 3, 1139
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm12031139
URN:NBNurn:nbn:hr:105:702457
Publication2023-02-01
Document URLhttps://www.mdpi.com/2077-0383/12/3/1139
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-16 08:53:12